- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Erin Resources/MGC Pharmaceuticals Secure License to Grow Cannabis In Namibia
Erin Resources (ASX:ERI) announced that MGC Pharmaceuticals has secured the option to acquire a license to grow its proprietary Sativa L Cannabis (Hemp) strain in Namibia.
Erin Resources (ASX:ERI) announced that MGC Pharmaceuticals has secured the option to acquire a license to grow its proprietary Sativa L Cannabis (Hemp) strain in Namibia.
As quoted in the press release:
The option has been secured through one of the MGC founder’s existing business operations in Namibia which has been awarded the license. This option has been secured to roll the Namibian production license into MGC’s operations as part of the existing MGC acquisition consideration terms agreed with Erin, for no additional consideration. The MGC operations and initial production facilities are currently being established in Slovenia, following key commercial license approvals in the region announced on 11 June 2015, to enable the company to grow for up to eight (8) months of the year in the Northern Hemisphere outdoor operations.
Operation highlights:
- MGC secures option with Namibian company to acquire license to grow Sativa L Cannabis (Hemp)
- Provides immediate access to low cost growing operation in legal Cannabinoid (CBD) jurisdiction
- Material impact on near term cashflow‐ potential 50% increase in MGC operating cashflow from 2017
- Ability to quickly increase to full 12 month production cycle (from current 8 months in Slovenia)
- Namibian CBD license will permit MGC to grow an unlimited amount of product for processing and trade
- MGC’s existing CBD import/export license will enable increased target production of CBD resin in Slovenia and distribution under existing and future commercial offtake agreements
- Forms a key part of MGC’s strategy to establish operations in the Northern and Southern hemispheres ‐ enabling crops to be grown 365 days of the year
- Accelerates discussions with additional CBD offtake partners
- Strong support from the Namibian Government who welcome the investment in the region
Nativ Segev, CEO of MGC Pharmaceuticals, commented:
Securing the option to establish a growing operation in the Southern Hemisphere provides MGC with the ability to become a supplier of CBD extract all year round. By diversifying our operations geographically we will be able to generate cash flow to the business all year round. We also expect to be able to fill orders for CBD in countries where the supply dwindles out of season, making MGC a preferred supplier to many cosmetics and pharmaceuticals companies who require a constant supply of CBD.
Click here to read the full Erin Resources (ASX:ERI) press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.